New York-based ProPhase, a global provider of measurement expertise in clinical trials, and Malvern, Pa.-based YPrime, a clinical trial software products and services company, have formed a strategic partnership to develop digital products that create new clinical trial standardization processes and tools, from trial design and patient selection to using data analytics to improve endpoints and study results.
In announcing the collaboration called “ProPhase Prime,” chief executive officers of both companies underscored the opportunities the partnership offers to transform the clinical trial process, particularly the outcomes in studies that rely upon extensive interaction between the physician and the patient. The focus is on empowering research clinicians to contribute better data in real time by improving how assessments are conducted, and enriching the patient selection and ongoing evaluation process.
“The drug development process remains vulnerable to imperfect measurement of outcomes that inflate costs and create delays,” said ProPhase CEO Sofija Jovic, Ph.D., M.B.A., “ProPhase Prime combines our company’s deep expertise in measurement science with YPrime’s clinical trial software to create digital platforms that provide sites and sponsors with access to real-time, actionable data to power better outcomes.”
In addition to the existing ProPhase electronic clinical outcome assessments (eCOA) platform powered by YPrime, an electronic adaptation of an integrated screening tool designed to improve patient selection and mitigate data risks such as placebo response will be the first project between the two companies. The beta version is scheduled to preview in October and will be featured at CNS Summit, one of the flagship industry conferences, in Boca Raton, Fla., on Oct. 8.
“We fully expect to change the science of clinical trial development by providing intuitive and insightful software that captures traditional data more effectively, as well as providing new benchmarks for analysis,” said YPrime CEO Shawn Blackburn.
“Our collaboration is designed to improve the model for collection and measurement of key elements within a clinical trial, while empowering investigators and patients to drive innovation and improve accuracy of outcome data,” said Jovic.